血浆生物标志物预测临床前阿尔茨海默病纵向认知下降
这项前瞻性人群预后研究基于瑞典BioFINDER-1和美国WRAP两个前瞻性纵向队列,纳入171例Aβ阳性的认知未受损参与者,评估血浆P-tau181、P-tau217、P-tau231、胶质纤维酸性蛋白和神经丝轻链预测认知下降的能力;结果显示血浆P-tau217预测认知下降表现最佳,并可能作为脑脊液或PET的补充用于临床试验受试者筛选。
要点
- 在Aβ阳性认知未受损人群中,血浆P-tau217是预测mPACC和MMSE认知下降的最佳标志物。
- BioFINDER-1队列中血浆P-tau217预测mPACC下降的模型R²=0.41,优于仅协变量模型R²=0.23。
- WRAP队列验证血浆P-tau217与mPACC斜率相关(R²=0.13 vs 0.01,P=.01)。
核心结论
- 本研究中血浆P-tau217可预测临床前阿尔茨海默病患者的认知下降。
- 这些发现提示血浆P-tau217可能作为脑脊液或PET的补充,用于新型疾病修饰治疗临床试验的受试者筛选。
研究设计与样本
- 前瞻性人群预后研究,评估瑞典BioFINDER-1和WRAP两个前瞻性纵向队列的数据。
- BioFINDER-1队列数据收集时间为2010年2月8日至2020年10月21日,WRAP队列为2011年8月11日至2021年6月27日。
- 参与者为记忆门诊招募的认知未受损个体,BioFINDER-1以脑脊液Aβ42/40定义脑Aβ病理,WRAP以匹兹堡化合物B(PiB)正电子发射断层扫描(PET)定义。
- 共纳入564例有相关数据的Aβ阳性和Aβ阴性认知未受损参与者,其中171例Aβ阳性参与者纳入主要分析。
主要发现
- 主要分析纳入171例Aβ阳性认知未受损参与者,其中BioFINDER-1组119例(平均[SD]年龄73.0[5.4]岁,女性60.5%),WRAP组52例(平均[SD]年龄64.4[4.6]岁,女性65.4%)。
- BioFINDER-1队列中,血浆P-tau217是预测mPACC认知下降的最佳标志物(模型R²=0.41),也是预测MMSE认知下降的最佳标志物(模型R²=0.34),均优于仅协变量模型(mPACC:R²=0.23;MMSE:R²=0.04;两项比较P<.001)。
- WRAP队列验证结果:血浆P-tau217与mPACC斜率相关(R²=0.13 vs 仅协变量模型0.01;P=.01),与MMSE斜率相关(R²=0.29 vs 仅协变量模型0.24;P=.046)。
- 以血浆P-tau217为预测因子的稀疏模型被识别用于预测认知下降。
- 在假设性临床试验的富集功效计算中,使用血浆P-tau217富集可能随时间发生认知下降的认知未受损个体,可大幅降低样本量。
临床怎么用
- 作者认为血浆P-tau217可能作为脑脊液或PET的补充,用于新型疾病修饰治疗临床试验的受试者筛选。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid (Aβ) accumulation without symptoms. The duration of this phase differs greatly among individuals. While this disease phase has high relevance for clinical trial designs, it is currently unclear how to best predict the onset of clinical progression. OBJECTIVE: To evaluate combinations of different plasma biomarkers for predicting cognitive decline in Aβ-positive cognitively unimpaired (CU) individuals. DESIGN, SETTING, AND PARTICIPANTS: This prospective population-based prognostic study evaluated data from 2 prospective longitudinal cohort studies (the Swedish BioFINDER-1 and the Wisconsin Registry for Alzheimer Prevention [WRAP]), with data collected from February 8, 2010, to October 21, 2020, for the BioFINDER-1 cohort and from August 11, 2011, to June 27, 2021, for the WRAP cohort. Participants were CU individuals recruited from memory clinics who had brain Aβ pathology defined by cerebrospinal fluid (CSF) Aβ42/40 in the BioFINDER-1 study and by Pittsburgh Compound B (PiB) positron emission tomography (PET) in the WRAP study. A total of 564 eligible Aβ-positive and Aβ-negative CU participants with available relevant data from the BioFINDER-1 and WRAP cohorts were included in the study; of those, 171 Aβ-positive participants were included in the main analyses. EXPOSURES: Baseline P-tau181, P-tau217, P-tau231, glial fibrillary filament protein, and neurofilament light measured in plasma; CSF biomarkers in the BioFINDER-1 cohort, and PiB PET uptake in the WRAP cohort. MAIN OUTCOMES AND MEASURES: The primary outcome was longitudinal measures of cognition (using the Mini-Mental State Examination [MMSE] and the modified Preclinical Alzheimer Cognitive Composite [mPACC]) over a median of 6 years (range, 2-10 years). The secondary outcome was conversion to AD dementia. Baseline biomarkers were used in linear regression models to predict rates of longitudinal cognitive change (calculated separately). Models were adjusted for age, sex, years of education, apolipoprotein E ε4 allele status, and baseline cognition. Multivariable models were compared based on model R2 coefficients and corrected Akaike information criterion. RESULTS: Among 171 Aβ-positive CU participants included in the main analyses, 119 (mean [SD] age, 73.0 [5.4] years; 60.5% female) were from the BioFINDER-1 study, and 52 (mean [SD] age, 64.4 [4.6] years; 65.4% female) were from the WRAP study. In the BioFINDER-1 cohort, plasma P-tau217 was the best marker to predict cognitive decline in the mPACC (model R2 = 0.41) and the MMSE (model R2 = 0.34) and was superior to the covariates-only models (mPACC: R2 = 0.23; MMSE: R2 = 0.04; P < .001 for both comparisons). Results were validated in the WRAP cohort; for example, plasma P-tau217 was associated with mPACC slopes (R2 = 0.13 vs 0.01 in the covariates-only model; P = .01) and MMSE slopes (R2 = 0.29 vs 0.24 in the covariates-only model; P = .046). Sparse models were identified with plasma P-tau217 as a predictor of cognitive decline. Power calculations for enrichment in hypothetical clinical trials revealed large relative reductions in sample sizes when using plasma P-tau217 to enrich for CU individuals likely to experience cognitive decline over time. CONCLUSIONS AND RELEVANCE: In this study, plasma P-tau217 predicted cognitive decline in patients with preclinical AD. These findings suggest that plasma P-tau217 may be used as a complement to CSF or PET for participant selection in clinical trials of novel disease-modifying treatments.
引用
- Mattsson-Carlgren N, Salvadó G, Ashton NJ, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. 2023. PMID: 36745413. doi:10.1001/jamaneurol.2022.5272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。